MOUNTAIN VIEW, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Daniel Weiner, Ph.D., Senior Vice President, Software Products, will speak to leading academics, regulators, and members of the Japanese pharmaceutical industry attending the 7th Kitasato University-Harvard School of Public Health Symposium. The symposium will be held at the ANA Tokyo Hotel on October 24-25, 2006.
Dr. Weiner will give a presentation on modeling and simulation to support the U.S. Food and Drug Administration’s Critical Path Initiative. Dr. Weiner will join panelists from industry, government, and academia in a university- sponsored symposium entitled, “Advanced and Global Drug Development Techniques: Japan’s Critical Path Opportunities.” The symposium will feature perspectives on opportunities, challenges and supporting technical infrastructure to enable critical path clinical research in Japan. The session will also offer a forum for interdisciplinary panel discussion on areas of opportunity in the drug development and approval process presented by the Critical Path Initiative, including quantitative drug-disease modeling. Additional information can be found at http://www.pharm.kitasato-u.ac.jp/biostatis/Khsympo_main2006.html .
“Modeling and simulation continues to demonstrate its value for improving the quality of drug development decisions,” said Shawn O’Connor, Pharsight President, CEO and chairman. “The FDA Critical Path Initiative is a challenge to build model-based drug development into the pharmaceutical development process. Pharsight is pleased to participate in this distinguished gathering at Kitasato University and to offer its perspectives on the Critical Path Initiative with fellow practitioners and colleagues. We look forward to exchanging information and best practices on the strategic application of modeling and simulation to support drug development in Japan.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight Corporation
CONTACT: Investors, Douglas Sherk, or Jennifer Beugelmans,+1-415-896-6820, or Media, Jen Saunders, +1-646-277-8720, all of EVC Group,for Pharsight
